Increased levels of transforming growth factor-beta1 and -beta2 in the aqueous humor of patients with neovascular glaucoma

Ophthalmic Surgery Lasers and Imaging

Volumn 38, Issue 1, 2007, Pages 6-14

  Yu, Xiao Bo ^a   Sun, Xing Huai ^a   Dahan, Elie ^b   Guo, Wen Yi ^a   Qian, Shao Hong ^a   Meng, Fan Rong ^a   Song, Yue Lian ^a   Simon, Guy J Ben ^c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FILTERING OPERATION; HUMAN; MALE; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; SENILE CATARACT; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

AQUEOUS HUMOR; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 33846839282     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Brown GC, Magargal LE, Schachat A, Shah H. Neovascular glaucoma: etiologic considerations. Ophthalmology. 1984;91:315-320.
2. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K. 1948;68:137-180.
3. Ashton N. Retinal vascularization in health and disease. Am J Ophthalmol. 1957;44:7-17.
4. Boyd SR, Zachary I, Chakravarthy I, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120:1644-1650.
5. Kozawa T, Sone H, Okuda Y, et al. Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma [in Japanese]. Nippon Ganka Gakkai Zasshi. 1998;102:731-738.
6. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-237.
7. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
8. Chen KH, Wu CC, Roy S, Lee SM, Liu JH. Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999;40:2627-2632.
9. John T, Sassani JW, Eagle RC Jr. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90:721-728.
10. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion: a 10-year prospective study. Graefes Arch Exp Ophthalmol. 1990;228:281-296.
11. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-491. Erratum in Arch Ophthalmol. 1997;115:1275.
12. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-1778.
13. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect. 1999;1:1349-1365.
14. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A. 1987;84:5788-5792.
15. Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI. Neutrophil chemotaxis in response to TGF-beta isoforms (TGF-beta 1, TGF-beta 2, TGF-beta 3) is mediated by fibronectin. J Immunol. 1994;152:2456-2466.
16. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337-4345.
17. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247:597-604.
18. Kocher O, Madri JA. Modulation of actin mRNAs in cultured vascular cells by matrix components and TGF-beta 1. In Vitro Cell Dev Biol. 1989;25:424-434.
19. Masszi A, Di Ciano C, Sirokmany G, et al. Central role for Rho in TGF-beta 1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2003;284:F911-F924.
20. Ghassemifar MR, Tarnuzzer RW, Chegini N, Tarpila E, Schultz GS, Franzen LE. Expression of alpha-smooth muscle actin, TGF-beta I and TGF-beta type II receptor during connective tissue contraction. In Vitro Cell Dev Biol Anim. 1997;33:622-627.
21. Hales AM, Schulz MW, Chamberlain CG, McEvoy JW. TGF-beta I induces lens cells to accumulate alpha-smooth muscle actin, a marker for subcapsular cataracts. Curr Eye Res. 1994;13:885-890.
22. Kurosaka D, Muraki Y, Inoue M, Katsura H. TGF-beta 2 increases alpha-smooth muscle actin expression in bovine retinal pigment epithelial cells. Curr Eye Res. 1996;15:1144-1147.
23. Kurosaka H, Kurosaka D, Kato K, Mashima Y, Tanaka Y. Transforming growth factor-beta I promotes contraction of collagen gel by bovine corneal fibroblasts through differentiation of myofibroblasts. Invest Ophthalmol Vis Sci. 1998;39:699-704.
24. Arora PD, Narani N, McCulloch CA. The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. Am J Pathol. 1999;154:871-882.
25. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963-969.
26. Ohara K, Funatsu H, Kitano S, Hori S, Yamashita H. The role of cytokines in the pathogenesis of diabetic retinopathy [in Japanese]. Nippon Ganka Gakkai Zasshi. 2001;105:213-217.
27. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol. 2002;46:249-253.
28. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
29. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239:109-113.
30. Critchlow MA, Bland YS, Ashhurst DE. The effect of erogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone. 1995;16:521-527.
31. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41:756-763.
32. Roberts AB, Sporn ME, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
33. Whitby DJ, Ferguson MW. Immunohistochemical localization of growth factors in fetal wound healing. Dev Biol. 1991;147:207-215.
34. Cordeiro MF. Beyond mitomycin: TGF-beta and wound healing. Prog Retin Eye Res. 2002;21:75-89.
35. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains as increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
36. Goftanka J, Chan D, Eichhorn M, Lutjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
37. Grainger DJ, Percival J, Chiano M, Spector TD. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int. 1999;9:398-404.
38. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroids. Invest Ophthalmol Vis Sci. 1993;34:477-487.
39. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res. 1991;10:761-771.
40. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect. 1999;1:1349-1365.
41. Li DQ, Lee SB, Tseng SC. Differential expression and regulation of TGF-beta 1, TGF-beta 2, TGF-beta 3, TGF-beta RI, TGF-beta RII and TGF-beta RIII in cultured human corneal, limbal, and conjunctival fibroblasts. Curr Eye Res. 1999;19:154-161.
42. Heino J, Ignotz RA, Hemler ME, Crouse C, Massague J. Regulation of cell adhesion receptors by transforming growth factor-beta: concomitant regulation of integrins that share a common beta I subunit. J Biol Chem. 1989;264:380-388.
43. Hertle MD, Jones PH, Groves RW, Hudson DL, Watt FM. Integrin expression by human epidermal keratinocytes can be modulated by interferon-gamma, transforming growth factor-beta, tumor necrosis factor-alpha, and culture on a dermal equivalent. J Invest Dermatol. 1995;104:260-265.
44. Riikonen T, Westermarok J, Koivisto L, Broberg A, Kahari VM, Heino J. Integrin alpha 2 beta I is a positive regulator of collagenase (MMP-1) and collagen alpha I (1) gene expression. J Biol Chem. 1995;270:13548-13552.
45. Schiro JA, Chan BM, Roswit WT, et al. Integrin alpha 2 beta I (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell. 1991;67:403-410.
46. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun. 1986;138:476-482.
47. Heimark RL, Twardzik DR, Schwartz SM. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science. 1986;233:1078-1080.
48. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994;269:6271-6274.
49. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A. 1987;84:5788-5792.
50. Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI. Neutrophil chemotaxis in response to TGF-beta isoforms (TGF-beta 1, TGF-beta 2, TGF-beta 3) is mediated by fibronectin. J Immunol. 1994;152:2456-2466.
51. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun. 1988;157:793-880.
52. Miller-Graziano CL, Szabo G, Griffey K, Mehta B, Kodys K, Catalano D. Role of elevated monocyte transforming growth factor beta (TGF beta) production in posttrauma immunosuppression. J Clin Immunol. 1991;11:95-102.
53. Riddick CA, Serio KJ, Hodulik CR, Ring WL, Regan MS, Bigby TD. TGF-beta increases leukotriene C4 synthase expression in the monocyte-like cell line, THP-1. J Immunol. 1999;162:1101-1107.
54. Ishida K, Yoshimura N, Yoshida M, Honda Y. Upregulation of transforming growth factor-beta after panretinal photocoagulation. Invest Ophthalmol Vis Sci. 1998;39:801-807.
55. Ie D, Gordon LW, Glaser BM, Pena RA. Transforming growth factor-beta 2 levels increase following retinal laser photocoagulation. Curr Eye Res. 1994;13:743-746.
56. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44:3394-3401.